Bioprinting Markets: Materials, Equipment and Applications – 2017 to 2027: An Opportunity Analysis and Ten-Year Forecast

Bioprinting Markets: Materials, Equipment and Applications – 2017 to 2027: An Opportunity Analysis and Ten-Year Forecast

  • April 2017 •
  • Report ID: 4865183 •
  • Format: PDF
SmarTech believes that the potential for the bioprinting sector has increased considerably in the past couple of years. What we are seeing is that (1) bioprinters themselves have technologically matured and (2) they have also become more accessible in terms of cost to a wider target of users -- low-cost desktop bioprinters are available at below $20,000.

Meanwhile, bioprinting is experiencing a rapid transformation from basic research in academic laboratories to an emerging industry due to its near-term potential in areas such as drug discovery, personalized medicine, regenerative medicine, cosmetics testing, medical devices and food manufacturing. While printing complete organs still seems a long way off, revenues from bioprinting are already being generated from these more immediate applications.

SmarTech’s analysis suggests that by 2027, bioprinting applications will generate over $1 billion in revenue, accompanied by a healthy market in specialist bioprinting hardware and materials.

This report explores the commercial implications of bioprinting in depth and includes:
Ten-year forecasts of bioprinting materials, hardware and applications markets. Materials are broken out by type and forecasted hardware is presented by both unit sales and in revenue terms, with breakouts by process technology and price point. Revenues for bioprinting applications are segmented by the type of application – specifically, drug discovery, cosmetics testing, medical devices and tissue regeneration.

Highly granular information about current pricing of both bioprinters and printing materials for bioprinting applications. In addition, the report provides detailed information on which companies and institutions are using bioprinters today and which printers they are using.

An assessment of the product/market strategies of emerging and established firms in the bioprinting space. While many of the firms pioneering this space are well-funded and innovative start-ups, bioprinting is also attracting the attention of some of the largest multinationals in big pharma and cosmetics, for example. Astellas Pharma, Bristol-Meyers Squibb, Merck, Novartis, Procter and Gamble, Roche and others all have bioprinting programs, as do some of the large research facilities in the world, such as the National Institutes of Health in the US. Meanwhile, bioprinting continues to be a favorite target of venture capital firms.

A full discussion of the latest developments in droplet and extrusion bio printer and what they mean both technically and from a business perspective. Also included is an analysis of the very diverse market for bioprinted materials. Emerging bioinks, include combinations of polymers, ceramics, cells, cell aggregates, peptides, growth factors, hydrogels, scaffold components, and other materials.

SmarTech believes that this report will become required reading for marketing and business development executives in the pharmaceutical, healthcare, consumer products, cosmetics, specialty chemical and other industries as well as those in the 3D printing/bioprinting sector itself. This report will also be considerable value to members of the investment community who are increasingly appraising opportunities in the bioprinting space.

We are very sorry, but an error occurred.
Please contact if the problem remains.